Evidence map›Paper›PMID 38820084›Full record

ArticleThe Journal of clinical endocrinology and metabolism2024

Novel Detection and Progression Markers for Diabetes Based on Continuous Glucose Monitoring Data Dynamics.

Eslam Montaser, Leon S Farhy, Boris P Kovatchev

Abstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eslam MontaserDivision of Endocrinology and Metabolism, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.ORCID 0000-0002-3138-1964
Leon S FarhyCenter for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0002-4712-7055
Boris P KovatchevCenter for Diabetes Technology, School of Medicine, University of Virginia, Charlottesville, VA 22903, USA.ORCID 0000-0003-0495-3901

Funding

Insulin-Glucose-Glucagon Network: Defining a type 1 diabetes progression modelDP3DK106907 · NIDDK · UNIVERSITY OF VIRGINIA · PI BROWN, SUE A, FARHI, LEON S · 2015 to 2015
$1.5M
Commonwealth Research Commercialization FundDexcom, IncEunice Kennedy Shriver National Institute of Child Health and Human Development, and the JDRFNational Institute of Allergy and Infectious DiseasesNIDDK NIH HHS DP3 DK106907NIH HHS DP3DK106907University of Virginia
6 · The paper itself

Abstract

contextStatic measures of continuous glucose monitoring (CGM) data, such as time spent in specific glucose ranges (70-180 mg/dL or 70-140 mg/dL), do not fully capture the dynamic nature of blood glucose, particularly the subtle gradual deterioration of glycemic control over time in individuals with early-stage type 1 diabetes.

objectiveDevelop a diabetes diagnostic tool based on 2 markers of CGM dynamics: CGM entropy rate (ER) and Poincaré plot (PP) ellipse area (S).

methodsA total of 5754 daily CGM profiles from 843 individuals with type 1, type 2 diabetes, or healthy individuals with or without islet autoantibody status were used to compute 2 individual dynamic markers: ER (in bits per transition; BPT) of daily probability matrices describing CGM transitions between 8 glycemic states, and the area S (mg2/dL2) of individual CGM PP ellipses using standard PP descriptors. The Youden index was used to determine "optimal" cut-points for ER and S for health vs diabetes (case 1); type 1 vs type 2 (case 2); and low vs high type 1 immunological risk (case 3). The markers' discriminative power was assessed through the area under the receiver operating characteristics curves (AUC).

resultsOptimal cutoff points were determined for ER and S for each of the 3 cases. ER and S discriminated case 1 with AUC = 0.98 (95% CI, 0.97-0.99) and AUC = 0.99 (95% CI, 0.99-1.00), respectively (cutoffs ERcase1 = 0.76 BPT, Scase1 = 1993.91 mg2/dL2), case 2 with AUC = 0.81 (95% CI, 0.77-0.84) and AUC = 0.76 (95% CI, 0.72-0.81), respectively (ERcase2 = 1.00 BPT, Scase2 = 5112.98 mg2/dL2), and case 3 with AUC = 0.72 (95% CI, 0.58-0.86), and AUC = 0.66 (95% CI, 0.47-0.86), respectively (ERcase3 = 0.52 BPT, Scase3 = 923.65 mg2/dL2).

conclusionCGM dynamics markers can be an alternative to fasting plasma glucose or glucose tolerance testing to identify individuals at higher immunological risk of progressing to type 1 diabetes.

Indexed as

BiomarkersBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Disease ProgressionAdolescentAdultChildContinuous Glucose MonitoringFemaleHumansMaleMiddle AgedYoung AdultBiomarkersBlood Glucosecontinuous glucose monitoringentropy rateislet autoantibodiesPoincaré plotstages of diabetestransition probability matrix

Identifiers

PMID38820084
PMCPMC11651704

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.